Zai Lab (09688) stated that on March 2, 2026 (U.S. Eastern Time), the company granted 8,000 American depositary shares (ADSs) in share options, representing 80,000 underlying ordinary shares. The exercise price per ADS is US$19.48, and the options are valid for ten years. According to the announcement, 25% of the options will vest on each anniversary of the grant date over a four-year period, contingent on continued employment. No performance targets or clawback mechanisms apply to these grants.

In addition, the company granted 12,344 ADSs in restricted share units (RSUs), representing 123,440 underlying ordinary shares. The RSUs are set to vest at a rate of 25% each year over four years, also dependent on continued employment. Similar to the options, there are no performance requirements or clawback measures. The reasons cited for these grants include recognizing and rewarding contributions and providing added motivation to employees.

After these transactions, Zai Lab reported that 80.07 million shares remain available for future grants under the 2024 Equity Incentive Plan, which was approved at the company’s 2024 annual general meeting. The announcement highlighted that none of the grantees are directors, chief executives, or substantial shareholders of the company, and no party involved exceeds the individual or 12-month limit requirements set forth in the Listing Rules.